Summary (10 sec read)
This article explores the potential of Botox injections in preventing xerostomia (dry mouth), a common side effect of Actinium-225 cancer therapy. Research suggests Botox may offer a promising solution for improving the quality of life for cancer patients undergoing this treatment.
Imagine struggling to enjoy a simple meal, having trouble speaking clearly, or constantly feeling parched. These are just some of the daily challenges faced by individuals living with xerostomia, or severe dry mouth.
Unfortunately, individuals battling cancer can face an increased risk of developing xerostomia as a side effect of certain treatments, including Actinium-225 (Ac-225) therapy. While Ac-225 therapy shows great promise in targeting cancer cells, it can inadvertently damage the salivary glands, leading to decreased saliva production and the uncomfortable symptoms of dry mouth.
However, there's hope on the horizon. A 2021 pilot study published by Y. Baum et al. investigated the use of Botox injections to prevent xerostomia in patients undergoing Ac-225 therapy. The study's results were encouraging, showing a significant reduction in the severity of dry mouth in patients who received Botox injections before their treatment. Botox, primarily known for its cosmetic applications, works by temporarily reducing saliva production. In the context of Ac-225 therapy, this reduction helps minimize the uptake of radioactive isotopes by the salivary glands, thus protecting them from radiation damage and lowering the chances of developing xerostomia.
Mechanism Summary:
- Neurotoxin Action: Botox blocks acetylcholine, preventing salivary stimulation.
- Reduced Radiation Absorption: With reduced gland activity, there is less uptake of radioactive isotopes like Actinium-225.
- Preservation of Salivary Gland Function: Temporary inhibition reduces radiation-induced fibrosis and maintains long-term gland function.
In a 2021 pilot study published by Y. Baum et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693763/], researchers investigated the efficacy of Botox injections in preventing xerostomia in patients undergoing Ac-225 PSMA therapy. The study involved a small cohort of 10 patients, each receiving Botox injections directly into the parotid and submandibular glands before the administration of Actinium-225 radiopharmaceuticals.
The results demonstrated a significant reduction in the severity of xerostomia, with the following key findings:
- 60% of patients reported no or mild dry mouth symptoms post-treatment, compared to a historical control group where 90% of patients reported moderate to severe xerostomia.
- MRI and scintigraphy of the salivary glands showed reduced uptake of the radiopharmaceuticals in Botox-treated patients.
- Long-term follow-up (6 months post-treatment) indicated that salivary function in Botox-treated patients returned to near-baseline levels, suggesting that the protective effect was temporary and did not cause permanent glandular dysfunction.
If you are planning your Actinium 225 or Pluvicto/Lutetium 177 therapy, do discuss these points with Dr. Ishita B Sen, our centre has a very advanced Plastic & Reconstructive Surgery department headed by Additional Director, Plastic and Reconstructive Surgery Dr Rashmi Taneja who will be willing to guide you on the benefits of Botox for prevention of Xerostomia post Ac 225 and Lu 177 therapy.
Additional Resources:
Frequently Asked Questions
-
What is xerostomia?
Xerostomia, commonly known as dry mouth, is a condition where the salivary glands do not produce enough saliva to keep the mouth moist. It can cause discomfort, difficulty in speaking, eating, and an increased risk of oral infections.
-
Why does xerostomia occur during Actinium-225 therapy?
Actinium-225 (Ac-225) therapy, while effective in targeting cancer cells, can inadvertently damage the salivary glands, leading to reduced saliva production and xerostomia. The radiation exposure from the therapy can cause fibrosis or scarring of the glands, reducing their function.
-
How can Botox help in preventing xerostomia during Ac-225 therapy?
Botox injections work by temporarily reducing salivary gland activity, which decreases the uptake of radioactive isotopes like Actinium-225 by the glands. This protects the glands from radiation damage, helping to prevent the onset of xerostomia.
-
Is Botox commonly used to treat xerostomia caused by cancer treatments?
While Botox is more commonly known for its cosmetic applications, its potential to treat xerostomia in patients undergoing nuclear medicine therapies like Ac-225 is gaining attention. A pilot study has shown promising results in reducing dry mouth symptoms.
-
What were the results of the 2021 pilot study involving Botox and Ac-225 therapy?
The 2021 study by Y. Baum et al. demonstrated that 60% of patients who received Botox injections before Ac-225 therapy reported no or mild xerostomia, compared to 90% of patients in a historical control group who reported moderate to severe symptoms. Additionally, MRI and scintigraphy showed reduced radiopharmaceutical uptake in the treated patients' salivary glands.
-
How long do the effects of Botox last for preventing xerostomia?
According to the study, Botox injections provided temporary protection to the salivary glands during Ac-225 therapy, with most patients’ salivary function returning to near-normal levels within six months of treatment.
-
Can Botox cause permanent damage to the salivary glands?
No, Botox does not cause permanent damage to the salivary glands. The effects are temporary, allowing the glands to return to their normal function after a period of time.
-
Should I consider Botox if I am undergoing Ac-225 or Lutetium-177 (Pluvicto) therapy?
If you are concerned about xerostomia during Ac-225 or Lutetium-177 therapy, it's a good idea to discuss Botox injections with your healthcare team. Specialists like Dr. Ishita B Sen and Dr. Rashmi Taneja may offer guidance on whether Botox is appropriate for your treatment plan.
-
Are there any risks associated with using Botox for xerostomia prevention?
As with any medical procedure, there are some risks associated with Botox injections, including localized discomfort or infection at the injection site. However, the procedure is generally considered safe when performed by a qualified healthcare provider.
Consult Dr Ishita B Sen